MARKET

HSTO

HSTO

Conatus Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.620
+0.080
+5.19%
After Hours: 1.640 +0.02 +1.23% 13:17 11/27 EST
OPEN
1.510
PREV CLOSE
1.540
HIGH
1.640
LOW
1.510
VOLUME
71.78K
TURNOVER
--
52 WEEK HIGH
7.50
52 WEEK LOW
1.300
MARKET CAP
24.32M
P/E (TTM)
-0.5550
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Histogen under pressure on $4.5M registered direct offering
Histogen (HSTO) to sell ~2.52M common shares at $1.78375/share, in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of ~$4.5M.Concurrently, the company will issue unregistered five
Seekingalpha · 11/12 13:34
Histogen reports Q3 results
Histogen (HSTO): Q3 GAAP EPS of -$0.27.Revenue of $0.49M (+58.1% Y/Y)Cash and cash equivalents of $6.6M.Press Release
Seekingalpha · 11/10 21:39
Histogen to Report Third Quarter 2020 Earnings on November 12, 2020
SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the third quarter ended September 30, 2020 will be released after the close of market on Thursday, November 12, 2020. About Histogen Inc.Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair. For more information, please visit www.histogen.com.CONTACT: Susan A. Knudson Executive Vice President & CFO Histogen Inc. ir@histogen.com
GlobeNewswire · 10/28 20:30
Histogen, Amerimmune inks emricasan agreement for COVID-19
Histogen (HSTO) ticks 2% higher in premarket on light volume after announcing an agreement with Amerimmune to jointly develop emricasan a caspase inhibitor, for the treatment of COVID-19.Additionally, the FDA has signed-off Phase 1
Seekingalpha · 10/27 12:48
Histogen Appoints Moya Daniels as Executive Vice President and Head of Regulatory, Quality and Clinical Operations
SAN DIEGO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced the appointment of Moya Daniels as Executive Vice President and Head of Regulatory, Quality and Clinical Operations. “I am pleased to have Moya join the Histogen team at this important time as we continue to progress our pipeline candidates in the clinic,” said Richard W. Pascoe, President and Chief Executive Officer of Histogen. “Moya has over 30 years of experience in the biotechnology and pharmaceutical industries and most notably has extensive expertise in the cell and gene therapy field. Moreover, Moya brings an impressive track-record to Histogen as an industry leader which will complement our existing senior management team.”Ms. Daniels most recently served as Senior Vice President of GMP Quality at SanBio, where she successfully led the CMC regulatory development and GMP Quality function in support of the planned Japan commercialization of their lead product candidate. Prior to SanBio, Ms. Daniels was the Senior Vice President of Regulatory Affairs and Global Quality Assurance at Orchard Therapeutics, where she led the company’s CMC regulatory and GXP quality strategy and was part of the team that led the in-licensing of GSK’s rare disease gene therapy portfolio. Prior to joining Orchard, Ms. Daniels served as Vice President of Regulatory Affairs and Quality Assurance at Fate Therapeutics, Inc, where she led the development of the global regulatory strategy and quality assurance function and was interim head of Clinical Operations. Moya led development of the global regulatory strategy, quality, and global clinical operations at Osiris Therapeutics, which led to the approval of Prochymal®, the first approved allogeneic cell therapy indicated for the treatment of pediatric steroid refractory acute Graft Versus Host Disease in Canada and New Zealand. Ms. Daniels also held a senior leadership position at Macrocure as Vice President of Global Regulatory Affairs and currently serves as a Scientific Advisory Board member for Indapta Therapeutics.“I am energized by Histogen’s leadership team and scientists and look forward to working with them to advance the company’s technology through clinical development. Histogen’s proprietary manufacturing process that generate biological materials that stimulate a patient’s own stem cells to activate and regenerate tissue is truly unique,” said Ms. Daniels. “Histogen’s focus on developing potential first-in-class restorative therapeutics is perfectly aligned with my industry experience and scientific passion.”About Histogen Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair. For more information, please visit www.histogen.com.Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward-looking statements when we discuss our future operations and our ability to successfully initiate and complete clinical trials, obtain clinical trial data and achieve regulatory milestones and related timing; the nature, strategy and focus of our business; the sufficiency of our cash resources and ability to achieve value for our stockholders; and the development and commercial potential and potential benefits of any of our product candidates. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of ours that could differ materially from those described in or implied by the statements in this press release, including: the uncertainties associated with the clinical development and regulatory approval of our product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; the potential that earlier clinical trials and studies of Histogen’s product candidates may not be predictive of future results; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase its costs and expenses; the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all; and the ability to attract and retain key personnel. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including those risks discussed in our filings with the Securities and Exchange Commission. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events, or circumstances or otherwise.CONTACT: Susan A. Knudson Executive Vice President & CFO Histogen Inc. ir@histogen.com
GlobeNewswire · 10/19 12:00
Histogen Announces Completion of Final Dosing Timepoint Milestone in its 1b/2a Trial for Androgenic Alopecia in Men
Top Line Results Remain on Track for Q4’2020SAN DIEGO, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological
GlobeNewswire · 10/05 13:00
Histogen perks up 7% on advancement of candidate for male pattern baldness
Dosing has been completed in a Phase 1b/2a clinical trial evaluating Histogen's (HSTO) lead candidate HST-001 for the treatment of androgenic alopecia (male pattern baldness).36 subjects, randomized 2:1 to receive
Seekingalpha · 10/05 12:39
Histogen's HST-002 designated as drug-biologic-device combination product
Histogen's ([[HSTO]] +0.7%) HST-002 is now designated as drug-biologic-device combination product by Office of Combination Products, a division of the FDA. In April of 2020, Histogen had submitted an Investigational Device Exemption
Seekingalpha · 09/29 14:12
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HSTO. Analyze the recent business situations of Conatus Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HSTO stock price target is 1.500 with a high estimate of 1.500 and a low estimate of 1.500.
EPS
Institutional Holdings
Institutions: 55
Institutional Holdings: 1.61M
% Owned: 10.73%
Shares Outstanding: 15.01M
TypeInstitutionsShares
Increased
3
39.88K
New
6
37.14K
Decreased
4
61.26K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.20%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Director
David Crean
President/Chief Executive Officer/Director
Richard Pascoe
Founder/Chief Scientific Officer
Gail Naughton
Chief Financial Officer/Executive Vice President
Susan Knudson
Executive Vice President
Moya Daniels
Senior Vice President
Daniel Ripley
Senior Vice President
Edward Smith
Vice President - Operations
Martin Latterich
Secretary
Thomas Hubka
Director
Stephen Chang
Director
Jonathan Jackson
Director
Steven Mento
Director
Brian Satz
Director
Hayden Yizhuo Zhang
Independent Director
Daniel Kisner
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About HSTO
Histogen Inc., formerly Conatus Pharmaceuticals Inc., is a regenerative medicine company. The Company is focused on developing technologies that replace and regenerates tissues in the body. The company’s technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells, developing therapeutic products that address unmet medical needs. The Company has product candidates in clinical development intended to address and offer treatment for hair loss, dermal filler and treatment for joint cartilage repair. The Company manufactures a soluble multipotent cell conditioned media (CCM), which is the starting material for products for hair growth, skin care and other applications. In addition to this, the Company also manufactures an insoluble extracellular matrix (ECM) for applications such as orthopedics, wound care and soft tissue augmentation.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Histogen Inc stock information, including NASDAQ:HSTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HSTO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HSTO stock methods without spending real money on the virtual paper trading platform.